Cytomegalovirus (CMV) is an important pathogen in transplant recipients and human
immunodeficiency virus (HIV)-infected individuals. Major progress has been made in …

Nucleoside analogues such as acyclovir and ganciclovir have been the mainstay of therapy
for alphaherpesviruses (herpes simplex virus (HSV) and varicella-zoster virus (VZV)) and …

Resistance of cytomegalovirus (CMV) to antiviral agents is a well-recognized phenomenon
that has been observed in the laboratory and in the clinical setting. Infections caused by …

Mutations in both the viral phosphotransferase gene, UL97, and the DNA polymerase gene,
UL54, have been shown to confer ganciclovir resistance to cytomegalovirus (CMV) …

Human cytomegalovirus (HCMV) infections are common and lead to lifelong infections. In
immunocompetent individuals, primary infections are mostly subclinical or they may be …

Objective To provide recommendations for the treatment of acquired immunodeficiency
syndrome–related cytomegalovirus (CMV) end-organ diseases, including retinitis, colitis …

In a human immunodeficiency virus-infected subject, cytomegalovirus (CMV) isolated 9
months after the patient began oral ganciclovir prophylaxis was resistant to ganciclovir and …

Studies report that 40-100% of the general population are infected with cytomegalovirus
(CMV), a virus associated with severe neurological conditions, such as CMV encephalitis …

Antiviral susceptibilities to ganciclovir, foscarnet, and cidofovir and sequencing of UL97 and
DNA polymerase were done on 23 cytomegalovirus (CMV) isolates from 10 …

This multicentre prospective cohort study by the EuroSIDA study group was designed to
determine the factors affecting the incidence of cytomegalovirus (CMV) end-organ disease …